|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2004-1-23
|
|
pubmed:abstractText |
Oxaliplatin (OHP) is a new platinum antineoplastic, while gemcitabine (GEM) is one of the most active drugs against non-small cell carcinoma (NSCLC). The OHP/GEM combination is interesting because the drugs have different mechanisms of action and toxicity profiles. The primary endpoint of this study was to determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of OHP/GEM combination in non-small cell carcinoma of the lung.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0169-5002
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
43
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
203-8
|
|
pubmed:dateRevised |
2006-4-24
|
|
pubmed:meshHeading |
pubmed-meshheading:14739041-Aged,
pubmed-meshheading:14739041-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:14739041-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:14739041-Deoxycytidine,
pubmed-meshheading:14739041-Female,
pubmed-meshheading:14739041-Humans,
pubmed-meshheading:14739041-Infusions, Intravenous,
pubmed-meshheading:14739041-Lung Neoplasms,
pubmed-meshheading:14739041-Male,
pubmed-meshheading:14739041-Maximum Tolerated Dose,
pubmed-meshheading:14739041-Middle Aged,
pubmed-meshheading:14739041-Neutropenia,
pubmed-meshheading:14739041-Organoplatinum Compounds,
pubmed-meshheading:14739041-Thrombocytopenia
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Phase I study of escalating doses of oxaliplatin in combination with fixed dose gemcitabine in patients with non-small cell lung cancer.
|
|
pubmed:affiliation |
Medical Oncology Unit B, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, Milano 20133, Italy.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase I
|
